Mark Bunnage Biography and Net Worth

Executive Vice President and Chief Scientific Officer of Vertex Pharmaceuticals

Mark’s passion for drug discovery and therapeutic innovation has driven his 30-year career, first as a medicinal chemist and then as a global scientific leader with a track record of pipeline growth, innovation and leadership. He joined Vertex in 2016 and leads the research strategy across all of Vertex’s Research sites (Boston; San Diego; Oxford, UK; Seattle; and Biologics, Cell & Genetic Therapies), as well as data and computational sciences, preclinical sciences and external innovation.

He graduated with a B.Sc. in chemistry from the University of Durham, UK, and a D.Phil. in chemistry from the University of Oxford, UK. Before joining Vertex, Mark had a distinguished 20-year career at Pfizer, where he held numerous leadership roles in medicinal chemistry.

Mark is a Fellow of the Royal Society of Chemistry (FRSC), a Fellow of the Royal Society of Biology (FRSB), and a visiting professor in chemistry at the University of Oxford. He is an author or inventor on over 80 publications and patents.

What is Mark E. Bunnage's net worth?: The estimated net worth of Mark E. Bunnage is at least $6.35 million as of February 11th, 2026. Dr. Bunnage owns 12,914 shares of Vertex Pharmaceuticals stock worth more than $6,346,844 as of February 15th. This net worth estimate does not reflect any other assets that Dr. Bunnage may own. Learn More about Mark E. Bunnage's net worth.
How do I contact Mark E. Bunnage?: The corporate mailing address for Dr. Bunnage and other Vertex Pharmaceuticals executives is 50 NORTHERN AVENUE, BOSTON MA, 02210. Vertex Pharmaceuticals can also be reached via phone at (617) 341-6100 and via email at [email protected]. Learn More on Mark E. Bunnage's contact information.
Has Mark E. Bunnage been buying or selling shares of Vertex Pharmaceuticals?: In the last ninety days, Mark E. Bunnage has sold $930,529.03 of Vertex Pharmaceuticals stock. Most recently, Mark E. Bunnage sold 2,021 shares of the business's stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $460.43, for a transaction totalling $930,529.03. Following the completion of the sale, the executive vice president now directly owns 12,914 shares of the company's stock, valued at $5,945,993.02. Learn More on Mark E. Bunnage's trading history.
Who are Vertex Pharmaceuticals' active insiders?: Vertex Pharmaceuticals' insider roster includes David Altshuler (EVP), Kristen Ambrose (CAO), Stuart Arbuckle (COO), E. Morrey Atkinson, III (EVP), Sangeeta Bhatia (Director), Jonathan Biller (EVP), Joshua Boger (Director), Carmen Bozic (CMO), Mark Bunnage (Executive Vice President and Chief Scientific Officer), Reshma FASN (M.D.), Reshma Kewalramani (CEO), Yuchun Lee (Director), Jeffrey Leiden (Chairman), Joy Liu (SVP), Margaret McGlynn (Director), Michael Parini (EVP), Amit Sachdev (EVP), Bruce Sachs (Director), Bastiano Sanna (EVP), Paul Silva (CAO), Ian Smith (COO), Ourania Tatsis (EVP), and Charles Wagner, Jr. (CFO). Learn More on Vertex Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Vertex Pharmaceuticals?: During the last year, Vertex Pharmaceuticals insiders bought shares 1 times. They purchased a total of 5,000 shares worth more than $1,948,400.00. During the last year, insiders at the pharmaceutical company sold shares 15 times. They sold a total of 176,701 shares worth more than $79,330,253.33. The most recent insider tranaction occured on February, 11th when CAO Kristen Ambrose sold 1,376 shares worth more than $633,551.68. Insiders at Vertex Pharmaceuticals own 0.2% of the company. Learn More about insider trades at Vertex Pharmaceuticals.
Information on this page was last updated on 2/11/2026.

Mark E. Bunnage Insider Trading History at Vertex Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/11/2026	Sell	2,021	$460.43	$930,529.03	12,914

Mark E. Bunnage Buying and Selling Activity at Vertex Pharmaceuticals

Vertex Pharmaceuticals Company Overview

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $491.47

$471.65

$503.88

50 Day Range

MA: $459.98

$437.01

$491.47

2 Week Range

Now: $491.47

$362.50

$519.68

Volume

2,917,761 shs

Average Volume

1,507,371 shs

Market Capitalization

$124.70 billion

P/E Ratio

32.06

Dividend Yield

N/A

Beta

0.3